Acrivon Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biopharmaceutical company pioneering a unique proteomics-based approach to precision medicine. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company designs and develops oncology therapeutics matched to patients whose tumors are predicted to be sensitive to specific treatments. Unlike traditional precision oncology methods that rely on genetic mutations, the AP3 platform measures compound-specific effects on the entire tumor cell protein signaling network. Acrivon's clinical pipeline is led by ACR-368 (prexasertib), a selective small-molecule CHK1/2 inhibitor in a potentially registrational Phase 2b trial for endometrial cancer. Its second clinical asset is ACR-2316, a novel, selective, dual WEE1/PKMYT1 inhibitor designed for superior single-agent activity.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Officially deprioritizing ovarian and bladder cancer indications for lead asset ACR-368 to focus clinical resources entirely on serous endometrial cancer, where high unmet medical needs and compelling clinical efficacy have been observed.
Expected impact: Optimizes cash burn and accelerates the path toward a confirmatory Phase 3 trial in endometrial cancer.
Leveraging the proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform to advance internally discovered cell cycle candidates, including the dual WEE1/PKMYT1 inhibitor ACR-2316 and the CDK11 inhibitor ACR-6840.
Expected impact: Establishes a robust, multi-asset precision oncology pipeline beyond the in-licensed lead candidate.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Acrivon acquired exclusive, worldwide rights to develop and commercialize ACR-368 (prexasertib). Under the agreement, Eli Lilly retains a right of first negotiation to reacquire the drug, establishing a potential direct exit or commercialization pathway.
Terms: Exclusive worldwide licensing terms (specific upfront and milestone payments are confidential).
Co-development, clinical validation, and commercialization of Acrivon's OncoSignature test as a companion diagnostic for ACR-368, leveraging Akoya's PhenoImager solution to identify patients most likely to respond to therapy.
Terms: Akoya will serve as the exclusive provider of the companion diagnostic test, pending regulatory approval and commercialization of ACR-368.